Navigation Links
Preclinical data shows 100 percent prevention and treatment of influenza with engineered human antibody
Date:9/10/2012

Cambridge, MA September 10, 2012 Visterra, Inc., developer of novel therapeutics to treat major diseases, today announced the presentation of positive data from a preclinical study evaluating the efficacy of the company's lead product candidate, VIS410, a broadly protective, fully human monoclonal antibody being developed for influenza A infections. Data from preclinical studies were presented today at the 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in San Francisco. These data were also selected by ICAAC to be included in the public communication highlights for the meeting.

Developed using Visterra's innovative platform, VIS410 targets a site on influenza hemagglutinin (HA) that is present across all influenza A subtypes and is resistant to mutation development. VIS410 demonstrated broad neutralization against all influenza A strains tested in vitro, and provided potent and specific protection in mouse models against a lethal dose of influenza A virus, both prophylactically and therapeutically. In prophylactic studies, 100% of healthy non-infected mice who received a single dose of VIS410 survived subsequent infection with either H1N1 or H3N2 influenza A virus. In post-infection therapeutic studies, 100% of mice treated with a single dose of VIS410 survived a lethal viral challenge of either H1N1 or H3N2 when antibody was administered up to 72 hours after infection.

"This data with VIS410 shows several ways that this drug candidate has promise for fighting influenza, including possible pandemic strains," said Donna Ambrosino, M.D., Chief Medical Officer of Visterra. "With VIS410, we have designed an antibody that targets the viral hemagglutinin protein (HA) to enable to healthy person or patient to prevent or treat an established infection. Secondly, we have designed VIS410 as an antibody that neutralizes both groups of viral strains for influenza A, Group 1 and Group 2 viruses, opening the pot
'/>"/>

Contact: Kathryn Morris
kathryn@theyatesnetwork.com
845-635-9828
The Yates Network
Source:Eurekalert

Page: 1 2 3 4

Related biology technology :

1. Karyopharm Therapeutics announces the Publication of Two Preclinical Studies on the Activity of Selective Inhibitors of Nuclear Export (SINE) in Acute Myeloblastic Leukemia (AML)
2. MultiCell Technologies Announces Positive Preclinical Results for MCT-465 and MCT-485 in Primary Liver Cancer In Vitro Models
3. AtheroNova Inc. Preclinical Study Demonstrates 95% Reduction in Arterial Plaque Formation
4. ChemoCentryx Presents Positive Results for Novel CCR2 Inhibitor in Preclinical Models of Diabetic Nephropathy at the 44th Annual Meeting of the American Society of Nephrology
5. Survey Shows Physicians Divided as Presidential Election Nears
6. Science study shows promiscuous enzymes still prevalent in metabolism
7. Study Shows Transition to Practice Programs Get Nurses Employed
8. Study shows availability of hydrogen controls chemical structure of graphene oxide
9. CSL Behring Data Shows 4-Factor Prothrombin Complex Concentrate Is As Effective and a More Rapid Treatment for Vitamin K Antagonist Reversal Than Current Standard of Care
10. New Revolutionary Femoral Access Site Closure Device Shows Unparalleled Efficacy, Safety & Ease of Use, in a Wide Range of Patients Including Patients With a Challenging Anatomy
11. Pharmacoeconomic Analysis Shows SURFAXIN® May Reduce Hospital Cost Associated with Reintubation in Premature Infants
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... Calif. , Jan. 14, 2014 As pet owners drew ... doubt many of them wrote: "Take better care of my furry ... even designer clothes and top-brand carrying cases to take the little ... parents might also feel compelled to buy some pricey toys at ...
(Date:1/14/2014)... Jan. 14, 2014 The largest international professional ... plants and therapeutic derivatives thereof has endorsed an ... researchers about the challenges of adulterated herb and ... The Society for Medicinal Plant ...
(Date:1/14/2014)... iLab Solutions, the leader in core facility management software, ... Strategy. In this role, Michelle will work with current and ... the development of iLab products. Her main goal will be ... the scientific community by offering the most advanced, user-friendly, and ...
(Date:1/14/2014)... 2014  RXi Pharmaceuticals Corporation (OTCQX: RXII), a biotechnology ... therapies addressing major unmet medical needs using RNA-targeted ... of Allowance from the United States Patent and ... (sd-rxRNA®), for the treatment of fibrosis. The patent ...
Breaking Biology Technology:New Year's Resolution: Give Pets the Gift of Top-Notch Health Care 2World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 2World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 3World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 4World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 5World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 6World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 7World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 8iLab Solutions Announces Michelle Detwiler as the New Director of Product Strategy 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 3
... MADISON, N.J., Nov. 20 At a meeting of the ... today, a dividend of fifty cents($0.50) per share on the ... 2009 to stockholders of record at the close of business,on ... Wyeth is one of the world,s largest research-driven pharmaceutical and,health ...
... SIAL ),announced today the global release of MISSION(R) ... QUALITY and iScale Oligos(TM) siRNA are,expected to allow researchers ... with the highest purity and quality siRNA required for ... be well suited to target,validation and pre-clinical siRNA testing. ...
... 20 Nephros, Inc. (Amex: NEP ), a medical device company developing ... an update on its operations and strategy. , , ... , Appointed James Scibetta ... Ernest Elgin III President and CEO , Submitted ...
Cached Biology Technology:Sigma-Aldrich Introduces MISSION(R) In VIVO QUALITY and iScale Oligos(TM) siRNA, a Superior Quality siRNA Designed for RNAi Research in Animal Models 2Nephros Provides Corporate Update 2Nephros Provides Corporate Update 3Nephros Provides Corporate Update 4Nephros Provides Corporate Update 5Nephros Provides Corporate Update 6Nephros Provides Corporate Update 7
(Date:4/24/2014)... fungus could now be treated in three days, rather than ... , Cryptococcus a form of yeast - ... research. They are found in many parts of the ... affect people with weakened immune systems. This infection kills up ... has tested the effects of the most commonly used drug ...
(Date:4/24/2014)... be improved with new insights into the make-up of ... the Amazon Basin have revealed unprecedented detail of the ... by comparing satellite maps with hundreds of field plots. ... more accurately the amount of carbon each tree can ... schemes, in which trees are given a cash value ...
(Date:4/24/2014)... of clear liquid can bend light, acting as a ... developed a new process to create inexpensive high quality ... , Because they,re so inexpensive, the lenses can ... to detect diseases in the field, scientific research in ... in classrooms. , "What I,m really excited about ...
Breaking Biology News(10 mins):Treatment for deadly yeast disease reduced to 3 days 2Amazon rainforest survey could improve carbon offset schemes 2Bake your own droplet lens 2Bake your own droplet lens 3
... While researching methods to increase the already well-recognized ... Illinois also found a way to prolong the vegetable,s ... study, the method is a natural and inexpensive way ... and won,t spoil so quickly on your refrigerator shelf. ...
... disease is the most common form of birth defect, ... the National Institutes of Health. Researchers from the University ... treat laboratory mice with one form of congenital heart ... caused by abnormally thick muscle. By suppressing a faulty ...
... vegetables are associated with higher Body Mass Index (BMI) ... to American University researchers in the journal Pediatric ... between the prices of fruit and vegetables and higher ... and assistant professor of public administration and policy at ...
Cached Biology News:Better broccoli, enhanced anti-cancer benefits with longer shelf life 2Better broccoli, enhanced anti-cancer benefits with longer shelf life 3Compound improves cardiac function in mice with genetic heart defect, MU study finds 2High cost of fruits, vegetables linked to higher body fat in young children 2
p230 trans Golgi Purified Anti-Human clone 15, Isotype Mouse IgG 1 , 50 µg Consult technical datasheet for details....
... Probes intensely fluorescent and highly photostable ... use in a variety of applications ... strong signal. Unfortunately, protein- and other ... may cause them to bind to ...
DNA Polymerase I Large (Klenow) Fragment is a DNA polymerase that lacks the 5'Cut Site3' exodeoxyribonuclease activity of intact DNA Polymerase I but it contains the 3'Cut Site5' exodeoxyribonuclease...
... Description: Proteinase K is a highly active and ... applications purified from the fungus T. album. It ... of N-substituted hydrophobic aliphatic and aromatic amino acids ... protease. Proteinase K is useful in purifying high ...
Biology Products: